Published in Emerg Infect Dis on March 01, 2003
Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis (2005) 3.15
West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis (2004) 3.00
Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis (2004) 2.06
West Nile virus: a growing concern? J Clin Invest (2004) 1.77
West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis (2006) 1.76
Detection of human anti-flavivirus antibodies with a west nile virus recombinant antigen microsphere immunoassay. J Clin Microbiol (2004) 1.59
Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. J Clin Microbiol (2005) 1.56
West Nile virus surveillance and diagnostics: A Canadian perspective. Can J Infect Dis (2003) 1.44
Detection of West Nile virus (WNV)-specific immunoglobulin M in a reference laboratory setting during the 2002 WNV season in the United States. Clin Diagn Lab Immunol (2003) 1.41
West Nile Virus: biology, transmission, and human infection. Clin Microbiol Rev (2012) 1.38
Persistence of West Nile virus in the central nervous system and periphery of mice. PLoS One (2010) 1.38
Emerging viral infections of the central nervous system: part 1. Arch Neurol (2009) 1.28
Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev (2008) 1.27
Progress on the development of therapeutics against West Nile virus. Antiviral Res (2009) 1.26
West Nile virus meningoencephalitis. Nat Clin Pract Neurol (2006) 1.22
Geographic factors contributing to a high seroprevalence of West Nile virus-specific antibodies in humans following an epidemic. Clin Vaccine Immunol (2006) 1.12
West Nile virus. Clin Lab Med (2010) 1.10
Recent progress in West Nile virus diagnosis and vaccination. Vet Res (2012) 1.09
Evaluation of a West Nile virus immunoglobulin A capture enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (2005) 1.05
Persistence of detectable immunoglobulin M antibodies up to 8 years after infection with West Nile virus. Am J Trop Med Hyg (2013) 1.05
Serologic surveillance for West Nile virus and other flaviviruses in febrile patients, encephalitic patients, and asymptomatic blood donors in northern Mexico. Vector Borne Zoonotic Dis (2010) 1.03
Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One (2012) 1.02
Utility of the focus technologies west nile virus immunoglobulin M capture enzyme-linked immunosorbent assay for testing cerebrospinal fluid. J Clin Microbiol (2004) 1.02
Persistence of West Nile virus-specific antibodies in viremic blood donors. Clin Vaccine Immunol (2007) 1.00
Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies. Clin Vaccine Immunol (2009) 0.99
Persistence of virus-specific immune responses in the central nervous system of mice after West Nile virus infection. BMC Immunol (2011) 0.99
Clinical utility of commercial enzyme immunoassays during the inaugural season of West Nile virus activity, Alberta, Canada. J Clin Microbiol (2005) 0.98
West Nile virus: A re-emerging pathogen revisited. World J Virol (2012) 0.94
Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies. Clin Vaccine Immunol (2010) 0.92
Neutralizing antibodies against West Nile virus identified directly from human B cells by single-cell analysis and next generation sequencing. Integr Biol (Camb) (2015) 0.89
Approaches for the development of rapid serological assays for surveillance and diagnosis of infections caused by zoonotic flaviviruses of the Japanese encephalitis virus serocomplex. J Biomed Biotechnol (2012) 0.89
IgG1 is pathogenic in Leishmania mexicana infection. J Immunol (2010) 0.87
West Nile virus state of the art report of MALWEST Project. Int J Environ Res Public Health (2013) 0.87
West Nile viral infection of equids. Vet Microbiol (2013) 0.85
Evaluation of an enzyme immunoassay for detection of immunoglobulin M antibodies to West Nile virus and the importance of background subtraction in detecting nonspecific reactivity. Clin Vaccine Immunol (2007) 0.85
Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol (2005) 0.84
Two case reports of neuroinvasive west nile virus infection in the critical care unit. Case Rep Infect Dis (2012) 0.83
Effect of serum heat-inactivation and dilution on detection of anti-WNV antibodies in mice by West Nile virus E-protein microsphere immunoassay. PLoS One (2012) 0.83
Use of Testing for West Nile Virus and Other Arboviruses. Emerg Infect Dis (2016) 0.82
Second international diagnostic accuracy study for the serological detection of West Nile virus infection. PLoS Negl Trop Dis (2013) 0.82
Naturally induced humoral immunity to West Nile virus infection in raptors. Ecohealth (2008) 0.82
A hamster-derived West Nile virus isolate induces persistent renal infection in mice. PLoS Negl Trop Dis (2013) 0.82
West nile virus. Transfus Med Hemother (2013) 0.81
Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines. Viral Immunol (2014) 0.81
North American encephalitic arboviruses. Neurol Clin (2008) 0.81
Utilization of follow-up specimens from viremic blood donors to assess the value of west nile virus immunoglobulin G avidity as an indicator of recent infection. Clin Diagn Lab Immunol (2005) 0.78
Emergence of human West Nile Virus infection in Sri Lanka. BMC Infect Dis (2015) 0.77
Long-term Death Rates, West Nile virus epidemic, Israel, 2000. Emerg Infect Dis (2005) 0.76
West Nile virus IgM and IgG antibodies three years post- infection. Hippokratia (2015) 0.75
West nile virus: current perspectives. Ochsner J (2003) 0.75
Differential West Nile fever ascertainment in the United States: a multilevel analysis. Am J Trop Med Hyg (2010) 0.75
Antibody Responses to Zika Virus Infections in Environments of Flavivirus Endemicity. Clin Vaccine Immunol (2017) 0.75
West Nile virus detection and commercial assays. Emerg Infect Dis (2005) 0.75
West Nile and St. Louis encephalitis virus antibody seroconversion, prevalence, and persistence in naturally infected pig-tailed macaques (Macaca nemestrina). Clin Vaccine Immunol (2006) 0.75
Emerging and reemerging neurologic infections. Neurohospitalist (2014) 0.75
Maculopapular rash and tremor are associated with West Nile fever and neurological syndromes. J Neurol Neurosurg Psychiatry (2007) 0.75
Of Mice and Men: Protective and Pathogenic Immune Responses to West Nile virus Infection. Curr Trop Med Rep (2015) 0.75
West Nile virus. Update for family physicians. Can Fam Physician (2005) 0.75
Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science (1999) 18.55
The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med (2001) 11.48
Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol (2000) 8.80
Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut. Science (1999) 7.97
Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet (2001) 6.49
Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J Clin Microbiol (2000) 4.61
The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis (2000) 3.86
Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis. Lancet (1999) 3.80
Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection. J Clin Microbiol (2000) 3.48
Antibody capture immunoassay detection of japanese encephalitis virus immunoglobulin m and g antibodies in cerebrospinal fluid. J Clin Microbiol (1982) 3.44
West Nile virus: a reemerging global pathogen. Emerg Infect Dis (2001) 3.27
Genetic analysis of West Nile New York 1999 encephalitis virus. Lancet (1999) 3.12
Use of immunoglobulin m cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol (2002) 3.02
Immunoglobulin M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis encephalitis. J Clin Microbiol (1984) 2.95
Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis (1985) 2.59
Detection of Japanese encephalitis virus immunoglobulin M antibodies in serum by antibody capture radioimmunoassay. J Clin Microbiol (1982) 2.10
Persistence of virus-specific IgM and clinical recovery after Japanese encephalitis. Am J Trop Med Hyg (1976) 1.35
Field trial of a Japanese encephalitis diagnostic kit. J Med Virol (1986) 1.05
Serum and cerebrospinal fluid immunoglobulins M, A, and G in Japanese encephalitis. J Clin Microbiol (1988) 1.00
Virus-specific antibody-producing cells in blood and cerebrospinal fluid in acute Japanese encephalitis. J Med Virol (1985) 0.98
West Nile virus activity--United States, July 31-August 7, 2002, and Louisiana, January 1-August 7, 2002. MMWR Morb Mortal Wkly Rep (2002) 0.95
Improved surveillance of Japanese encephalitis by detection of virus-specific IgM in desiccated blood specimens. Bull World Health Organ (1985) 0.91
Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med (2009) 17.89
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
West Nile virus. Lancet Infect Dis (2002) 7.97
Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis (2005) 6.09
Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis (2011) 6.06
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health (2008) 5.32
Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med (2003) 4.95
Neurologic manifestations and outcome of West Nile virus infection. JAMA (2003) 4.61
Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) (2008) 4.38
Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis (2007) 3.87
Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep (2010) 3.80
Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol (2005) 3.63
Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med (2003) 3.37
Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis (2005) 3.15
Phylogenetic analysis of North American West Nile virus isolates, 2001-2004: evidence for the emergence of a dominant genotype. Virology (2005) 3.14
Use of immunoglobulin m cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol (2002) 3.02
Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries. Clin Infect Dis (2013) 2.91
The epidemic of West Nile virus in the United States, 2002. Vector Borne Zoonotic Dis (2004) 2.86
Virus and antibody dynamics in acute west nile virus infection. J Infect Dis (2008) 2.84
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr (2007) 2.71
Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003-2004. Pediatrics (2006) 2.53
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis (2006) 2.30
Transcontinental movement of Asian genotype chikungunya virus. Emerg Infect Dis (2014) 2.15
Introducing a multi-site program for early diagnosis of HIV infection among HIV-exposed infants in Tanzania. BMC Pediatr (2010) 2.09
Adult clinical and immunologic outcomes of the national antiretroviral treatment program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr (2009) 2.07
Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis (2004) 2.06
Detection of RNA from a novel West Nile-like virus and high prevalence of an insect-specific flavivirus in mosquitoes in the Yucatan Peninsula of Mexico. Am J Trop Med Hyg (2009) 1.96
West nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease. J Infect Dis (2010) 1.88
Duplex microsphere-based immunoassay for detection of anti-West Nile virus and anti-St. Louis encephalitis virus immunoglobulin m antibodies. Clin Diagn Lab Immunol (2005) 1.87
Consensus amplification and novel multiplex sequencing method for S segment species identification of 47 viruses of the Orthobunyavirus, Phlebovirus, and Nairovirus genera of the family Bunyaviridae. J Clin Microbiol (2009) 1.87
Detection of North American eastern and western equine encephalitis viruses by nucleic acid amplification assays. J Clin Microbiol (2003) 1.84
Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health (2009) 1.82
The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved (2013) 1.75
Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg Infect Dis (2016) 1.68
Comparison of vero cell plaque assay, TaqMan reverse transcriptase polymerase chain reaction RNA assay, and VecTest antigen assay for detection of West Nile virus in field-collected mosquitoes. J Am Mosq Control Assoc (2002) 1.67
Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J Clin Microbiol (2003) 1.65
West Nile virus-associated flaccid paralysis. Emerg Infect Dis (2005) 1.64
Estimation of HIV prevalence, risk factors, and testing frequency among sexually active men who have sex with men, aged 18-64 years--New York City, 2002. J Urban Health (2007) 1.63
Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion (2008) 1.62
Increased recognition of Powassan encephalitis in the United States, 1999-2005. Vector Borne Zoonotic Dis (2008) 1.59
Early-season avian deaths from West Nile virus as warnings of human infection. Emerg Infect Dis (2003) 1.54
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS One (2012) 1.46
Pregnancy desires, and contraceptive knowledge and use among prevention of mother-to-child transmission clients in Rwanda. AIDS (2009) 1.46
Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007. Am J Trop Med Hyg (2008) 1.43
Systemic collapse: Medical care in the aftermath of Hurricane Katrina. Biosecur Bioterror (2006) 1.41
West Nile virus epizootiology in the southeastern United States, 2001. Vector Borne Zoonotic Dis (2005) 1.41
West Nile virus neuroinvasive disease incidence in the United States, 2002-2006. Vector Borne Zoonotic Dis (2008) 1.39
Detection of West Nile virus-infected mosquitoes and seropositive juvenile birds in the vicinity of virus-positive dead birds. Am J Trop Med Hyg (2002) 1.36
HIV incidence in sub-Saharan Africa: a review of available data with implications for surveillance and prevention planning. AIDS Rev (2009) 1.35
West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis (2006) 1.35
Patients enrolled in HIV care in Mozambique: baseline characteristics and follow-up outcomes. J Acquir Immune Defic Syndr (2011) 1.32
High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS One (2013) 1.32
Interim Guidelines for the Evaluation and Testing of Infants with Possible Congenital Zika Virus Infection - United States, 2016. MMWR Morb Mortal Wkly Rep (2016) 1.29
High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers. Sex Transm Dis (2011) 1.28
Clinicopathologic study and laboratory diagnosis of 23 cases with West Nile virus encephalomyelitis. Hum Pathol (2004) 1.26
Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr (2010) 1.25
A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol (2012) 1.24
Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc (2011) 1.24
Molecular characterization of medically important viruses of the genus Orthobunyavirus. J Gen Virol (2008) 1.22
TB diagnostic capacity in sub-Saharan African HIV care settings. J Acquir Immune Defic Syndr (2012) 1.22
Second human case of Cache Valley virus disease. Emerg Infect Dis (2006) 1.21
Colon cancer screening practices in New York City, 2003: results of a large random-digit dialed telephone survey. Cancer (2005) 1.21
Dual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers. PLoS One (2011) 1.20
Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. AIDS (2010) 1.19
Hospital preparedness for pandemic influenza. Biosecur Bioterror (2006) 1.19
Association of adherence support and outreach services with total attrition, loss to follow-up, and death among ART patients in sub-Saharan Africa. PLoS One (2012) 1.19
Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS (2014) 1.17
West Nile virus infection among pregnant women in a northern Colorado community, 2003 to 2004. Pediatrics (2006) 1.17
Racial/ethnic differences in screening for colon cancer: report from the New York Cancer Project. Ethn Dis (2005) 1.17
High burden of prevalent and recently acquired HIV among female sex workers and female HIV voluntary testing center clients in Kigali, Rwanda. PLoS One (2011) 1.14
Evaluation of a diagnostic algorithm using immunoglobulin M enzyme-linked immunosorbent assay to differentiate human West Nile Virus and St. Louis Encephalitis virus infections during the 2002 West Nile Virus epidemic in the United States. Clin Diagn Lab Immunol (2004) 1.14
Delayed mortality in a cohort of persons hospitalized with West Nile virus disease in Colorado in 2003. Vector Borne Zoonotic Dis (2011) 1.13
Effect of Hurricane Katrina on arboviral disease transmission. Emerg Infect Dis (2007) 1.12
Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin Infect Dis (2006) 1.08
Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors. J Infect Dis (2008) 1.08
Isolation and full genomic characterization of Batai virus from mosquitoes, Italy 2009. J Gen Virol (2013) 1.08
Novel arenavirus infection in humans, United States. Emerg Infect Dis (2011) 1.07
Survival rates in NYC in the era of combination ART. J Acquir Immune Defic Syndr (2002) 1.07
Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg (2004) 1.04
Factors associated with loss to clinic among HIV patients not yet known to be eligible for antiretroviral therapy (ART) in Mozambique. J Int AIDS Soc (2013) 1.03
Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda. AIDS (2015) 1.01
Nucleic acid amplification assays for detection of La Crosse virus RNA. J Clin Microbiol (2005) 1.01
Mercury exposure and malaria prevalence among gold miners in Pará, Brazil. Rev Soc Bras Med Trop (2003) 0.99
La Crosse virus in Aedes albopictus mosquitoes, Texas, USA, 2009. Emerg Infect Dis (2010) 0.97
Primary causes of death in reported cases of fatal West Nile Fever, United States, 2002-2006. Vector Borne Zoonotic Dis (2010) 0.97
Incident sexually transmitted infections among persons living with diagnosed HIV/AIDS in New York City, 2001-2002: a population-based assessment. Sex Transm Dis (2007) 0.96
Toscana virus infection in American traveler returning from Sicily, 2009. Emerg Infect Dis (2010) 0.96